Telmisartan/hydrochlorothiazide

Telmisartan/hydrochlorothiazide
Combination of
Telmisartan	Angiotensin II receptor antagonist
Hydrochlorothiazide	Thiazide diuretic
Clinical data
Trade names	Micardis Plus, Micardis HCT, others
AHFS/Drugs.com	Professional Drug Facts
License data	US DailyMed: Telmisartan and hydrochlorothiazide;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	C09DA07 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
CAS Number	485391-74-0;
PubChem CID	216293;
KEGG	D09219 ;
CompTox Dashboard (EPA)	DTXSID30964080 ;
Chemical and physical data
Formula	C40H38ClN7O6S2
Molar mass	812.36 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCC1=NC2=C(N1CC3=CC=C(C=C3)C4=CC=CC=C4C(=O)O)C=C(C=C2C)C5=NC6=CC=CC=C6N5C.C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl;
	InChI InChI=1S/C33H30N4O2.C7H8ClN3O4S2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39;8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39);1-2,10-11H,3H2,(H2,9,12,13); Key:OZCVMXDGSSXWFT-UHFFFAOYSA-N;
	(verify)

Telmisartan/hydrochlorothiazide, sold under the brand name Micardis HCT among others, is a fixed-dose combination medication used to treat high blood pressure. It is a combination of telmisartan an angiotensin II receptor antagonist with hydrochlorothiazide a diuretic. It may be used if telmisartan by itself is not sufficient. It is taken by mouth.

Common side effects include dizziness, upper respiratory tract infections, nausea, diarrhea, and tiredness. Severe side effects may include kidney problems, electrolyte problems, and allergic reactions. Use during pregnancy may harm the baby. Telmisartan works by blocking the effects of angiotensin II while hydrochlorothiazide works by decreasing the kidneys' ability to retain water.

The combination was approved for medical use in the United States in November 2000, and in the European Union in April 2002. The combination is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.